Aetna partners with Fresenius Medical Care to improve lives of people with end stage renal disease

Fresenius Medical Care (NYSE: FMS) and Aetna (NYSE: AET) announced today a collaborative care model designed to improve the quality of care for Aetna's Medicare Advantage members who have end stage renal disease, while lowering health care costs.

Fresenius Medical Care North America's (FMCNA) nationally-recognized care management program is accredited by the National Committee for Quality Assurance, and creates a new approach for the overall delivery of care focused squarely on the unique needs of dialysis patients. Through this collaboration, Aetna nurse case managers will work closely with FMCNA staff on quality and care management for Aetna Medicare Advantage members who are receiving care at an FMCNA clinic. Aetna and FMCNA will work together to improve the health outcomes of these patients by boosting adherence to best practices and treatment plans.

"We are proud to collaborate with Aetna and deliver the resources and customized therapies necessary to improve the lives of people living with end stage renal disease," said Ron Kuerbitz, Chief Executive Officer of Fresenius Medical Care North America. "This collaboration embodies a truly integrated approach to serving the full spectrum of health care needs for this vulnerable population."

"Aetna is committed to helping our Medicare members work with their doctors to improve their quality of life by better managing the conditions contributing to or resulting from chronic kidney disease," said Robert Mirsky, M.D., Aetna's chief medical officer for Medicare. "We value our collaboration with Fresenius Medical Care and the complementary capabilities they can provide to improve the care our members receive from them."

This collaboration builds upon the relationship between Fresenius Medical Care and Aetna, who continue to expand a joint program to identify Aetna Medicare members with chronic kidney disease, and provide education, training and care management designed to ease what can be a difficult transition to dialysis or pre-transplant care.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Diabetes drug semaglutide proves beneficial for patients with chronic kidney damage and obesity